Amgen Submits Denosumab BLA Ahead Of Expectations
This article was originally published in The Pink Sheet Daily
Executive Summary
Novel RANK ligand inhibitor could have Oct. 19, 2009, PDUFA date.
You may also be interested in...
Will Safety Issues Derail Denosumab? FDA Sets Advisory Cmte. Slot
Amgen’s much-ballyhooed monoclonal antibody, now called Prolia, faces safety questions at the Aug. 13 Advisory Committee for Reproductive Health Drugs meeting.
Will Safety Issues Derail Denosumab? FDA Sets Advisory Cmte. Slot
Amgen’s much-ballyhooed monoclonal antibody, now called Prolia, faces safety questions at the Aug. 13 Advisory Committee for Reproductive Health Drugs meeting.
Likely Sales Slump Puts (Still More) Heat On Amgen’s Denosumab To Win
Analyst questions whether the bone drug’s efficacy can beat Zometa’s by the necessary 15 percent.